Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Our current efforts are focused on orthopedic treatments using our Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue).
Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Our lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product in the United States for the cartilage repair market (Agili-C was recently approved by the FDA).
GelrinC potentially offers a solution that gives surgeons a cost-effective product and a simple-to-perform procedure providing patients with sustained pain relief and functional improvement. GelrinC is already approved as a device with a CE mark in Europe, and we plan to look for strategic partners in Europe in connection therewith. In the US, we are conducting clinical trials towards PMA (see clinical development). With GelrinC, we aim to develop a product for the treatment of an unmet need for the market of cartilage injuries in the knee.
We believe our product offers a simple, effective and economic procedure, allowing patients for a comparatively quick recovery with potential for long-term efficacy outcomes. In addition, we have 46 granted patents and 8 pending patent applications covering, in a large number of countries, compositions, delivery device, surgical and manufacturing features.